{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:14Z","timestamp":1761058274843},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.gtc.2004.02.009","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"285-301","source":"Crossref","is-referenced-by-count":9,"title":["Crohn's disease: future anti\u2013tumor necrosis factor therapies beyond infliximab"],"prefix":"10.1016","volume":"33","author":[{"given":"Joshua R","family":"Korzenik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2004.02.009_BIB1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.009_BIB5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Group AIS. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.009_BIB7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB8","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/1529-0131(200009)43:9<1941::AID-ANR4>3.0.CO;2-O","article-title":"The anti-inflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis","volume":"43","author":"Rodenburg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gtc.2004.02.009_BIB9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","article-title":"Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease","volume":"40","author":"Bauditz","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/gast.2001.24042","article-title":"An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial","volume":"120","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.009_BIB14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-2036.1997.00251.x","article-title":"Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571","volume":"11","author":"Evans","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.009_BIB15","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0002-9270(01)02494-7","article-title":"Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives","volume":"96","author":"Blam","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2567.2002.01329.x","article-title":"Tumour necrosis factor in mouse models of chronic intestinal inflammation","volume":"105","author":"Mueller","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2249.1991.tb05688.x","article-title":"Induction of anti-mycobacterial and anti-listerial activity of human monocytes requires different activation signals","volume":"85","author":"Zerlauth","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1378\/chest.107.4.1074","article-title":"Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs","volume":"107","author":"Eggimann","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.gtc.2004.02.009_BIB20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1046\/j.1365-2362.2000.00751.x","article-title":"Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight loss","volume":"30","author":"Bossola","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.gtc.2004.02.009_BIB21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/qjmed\/89.11.831","article-title":"Systemic immune activation as a potential determinant of wasting in Zambians with HIV-related diarrhoea","volume":"89","author":"Kelly","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.gtc.2004.02.009_BIB22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(00)80009-4","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.009_BIB23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00003246-200103000-00006","article-title":"Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients","volume":"29","author":"Abraham","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/gut.40.4.443","article-title":"Tumour necrosis factor and Crohn's disease","volume":"40","author":"van Deventer","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","article-title":"Function and activation of NF-[kappa]B in the immune system","volume":"12","author":"Baeuerle","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB26","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1378\/chest.116.suppl_1.54S","article-title":"An intracellular signaling pathway linking lipopolysaccharide stimulation to cellular responses of the human neutrophil: the p38 MAP kinase cascade and its functional significance","volume":"116","author":"Nick","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.gtc.2004.02.009_BIB27","doi-asserted-by":"crossref","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF01540912","article-title":"Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease","volume":"16","author":"Reimund","year":"1996","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.med.45.1.491","article-title":"Tumor necrosis factor: a pleiotropic cytokine and therapeutic target","volume":"45","author":"Tracey","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB30","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2001.29035","article-title":"Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease","volume":"121","author":"van Deventer","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB31","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM199006073222302","article-title":"Activation of coagulation after administration of tumor necrosis factor to normal subjects","volume":"322","author":"Van der Poll","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB32","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/gut.40.4.475","article-title":"In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease","volume":"40","author":"Reimund","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB34","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1096-9926(200012)62:6<432::AID-TERA11>3.0.CO;2-Z","article-title":"The re-emergence of thalidomide: results of a scientific conference","volume":"62","author":"Neiger","year":"2000","journal-title":"Teratology"},{"issue":"Suppl 3","key":"10.1016\/j.gtc.2004.02.009_BIB36","first-page":"47","article-title":"Small therapeutic molecules for the treatment of inflammatory bowel disease","volume":"50","author":"van Deventer","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/07853890108995961","article-title":"Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature","volume":"33","author":"Ginsburg","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0006-2952(99)00388-3","article-title":"Mechanism of action in thalidomide teratogenesis","volume":"59","author":"Stephens","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB39","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s004170050330","article-title":"Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005176-199708000-00034","article-title":"Thalidomide in oral Crohn's disease refractory to conventional medical treatment","volume":"25","author":"Odeka","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.gtc.2004.02.009_BIB41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(05)64206-7","article-title":"Thalidomide in Crohn's disease","volume":"350","author":"Wettstein","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2004.02.009_BIB42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/bmj.1.6166.792","article-title":"Treatment of ulcerative colitis with thalidomide","volume":"1","author":"Waters","year":"1979","journal-title":"BMJ"},{"key":"10.1016\/j.gtc.2004.02.009_BIB43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1440-1746.2002.02564.x","article-title":"Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease","volume":"17","author":"Bariol","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.009_BIB45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004836-200208000-00006","article-title":"Thalidomide as \u201csalvage\u201d therapy for patients with delayed hypersensitivity response to infliximab: a case series","volume":"35","author":"Kane","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/gut.40.4.559","article-title":"Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease","volume":"40","author":"MacDonald","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2004.02.009_BIB47","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1111\/j.1572-0241.2001.04705.x","article-title":"Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial","volume":"96","author":"D'Haens","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.62.1.74","article-title":"Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis","volume":"62","author":"Marzo-Ortega","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gtc.2004.02.009_BIB50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.009_BIB51","first-page":"2350","article-title":"High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease","volume":"97","author":"Martinez-Borra","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB52","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB53","doi-asserted-by":"crossref","first-page":"A655","DOI":"10.1016\/S0016-5085(00)84761-7","article-title":"A randomized, double-blind, placebo-controlled trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease","volume":"118","author":"Feagan","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2001.00956.x","article-title":"Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease","volume":"15","author":"Cornillie","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2004.02.009_BIB55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/clim.2001.5183","article-title":"Immune function in patients with rheumatoid arthritis treated with etanercept","volume":"103","author":"Moreland","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.gtc.2004.02.009_BIB56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB57","doi-asserted-by":"crossref","first-page":"I48","DOI":"10.7326\/0003-4819-138-10-200305200-00004","article-title":"Tumor necrosis factor antagonists and heart failure","volume":"138","author":"Summaries for patients","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB58","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.gtc.2004.02.009_BIB59","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2004.02.009_BIB60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2004.02.009_BIB61","unstructured":"Document FB. Update on the TNF blocking agents. Available at: www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3930B1_01_B-TNF.Briefing.doc 2003. Accessed March 4, 2003."}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985530400024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985530400024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T17:14:41Z","timestamp":1550078081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985530400024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S088985530400024X"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2004.02.009","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}